As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
BCR's 20th Anniversary
20 years ago Breast Cancer Research published its first articles with BMC. Well-respected in the field, the journal has continually placed in the first quartile of the ‘Oncology’ category of Journal Citation Reports. Over the past decade, Breast Cancer Research (BCR) has also become the highest ranked breast cancer focused title in the field.
Look back at the journal’s milestone achievements and article highlights.
2019 Article Collection: Breast Cancer Epidemiology and Prevention
Breast Cancer Research is excited to present a curated collection on how different lifestyles, health, and populations are linked to breast cancer. Edited by one of our Deputy Editors, Dr. Leslie Bernstein is a leading epidemiologist in identifying physical activity as a means to reduce the risk of breast cancer. Find the collection here.
Aims and scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
Articles
-
-
High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer
-
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
-
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
-
MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth
-
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
-
Choosing the right cell line for breast cancer research
-
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
-
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin
-
Mouse models of breast cancer metastasis
Editor-in-Chief
Lewis Chodosh, University of Pennsylvania, USA
Trending in the Media
Click here to see the most popular articles published in Breast Cancer Research in the past three months.
From the blog
Advertisement
Follow
Annual Journal Metrics
-
Speed
83 days to first decision for reviewed manuscripts only
37 days to first decision for all manuscripts
173 days from submission to acceptance
30 days from acceptance to publicationCitation Impact
5.676 - 2-year Impact Factor
6.302 - 5-year Impact Factor
1.77 - Source Normalized Impact per Paper (SNIP)
2.874 - SCImago Journal Rank (SJR)Usage
1,803,016 Downloads
890 Altmetric Mentions
Advertisement
